Market closedNon-fractional

Protagonist Therapeutics/PTGX

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Protagonist Therapeutics

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Ticker

PTGX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Newark, United States

Employees

124

PTGX Metrics

BasicAdvanced
$2B
Market cap
12.80
P/E ratio
$2.70
EPS
2.08
Beta
-
Dividend rate
$2B
2.08
15.724
15.611
0.082
21.38%
41.75%
12.8
6.52
3.6
3.6
-31.99
36,565.08%
-195.36%
116.19%
14.12%

What the Analysts think about PTGX

Analyst Ratings

Majority rating from 6 analysts.
Buy

PTGX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
81.32% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$255M
324.83%
Net income
$207M
659.34%
Profit margin
81.32%
78.73%

PTGX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 173.08%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.68
-$0.58
$0.44
$3.26
-
Expected
-$0.65
-$0.69
-$0.03
$1.19
-$0.60
Surprise
5.05%
-16.41%
-1,425.30%
173.08%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Protagonist Therapeutics stock?

Protagonist Therapeutics (PTGX) has a market cap of $2B as of July 05, 2024.

What is the P/E ratio for Protagonist Therapeutics stock?

The price to earnings (P/E) ratio for Protagonist Therapeutics (PTGX) stock is 12.8 as of July 05, 2024.

Does Protagonist Therapeutics stock pay dividends?

No, Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Protagonist Therapeutics dividend payment date?

Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders.

What is the beta indicator for Protagonist Therapeutics?

Protagonist Therapeutics (PTGX) has a beta rating of 2.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Protagonist Therapeutics stock

Buy or sell Protagonist Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing